Table 2
Hep Par 1 negative cases
| Case | Tumour type | Immunohistochemical markers (extent of staining) | Clinical correlates | ||||
|---|---|---|---|---|---|---|---|
| AFP | CG | SYN | VI | Stage | Outcome | ||
| AC, adenocarcinoma; AIS, adenocarcinoma in situ; A+W, alive and well; Met, metastases; NFU, no follow up data available; Rec, local recurrence; SCC, squamous cell carcinoma. | |||||||
| 8 | AC | − | 10% | Focal | − | IB1 | A+W |
| 9 | AC | − | Focal | − | − | IB1 | A+W |
| 10–25 | SCC | − | − | − | 5/16 | I (10) | A+W |
| II (4) | 1 Rec,1 Met | ||||||
| III (2) | A+W | ||||||
| 26–27 | AC | − | − | − | − | IB1, IIA | A+W, NFU |
| 28 | AC+AIS | − | − | − | − | IB1 | A+W |
| 29 | AIS | − | − | − | − | − | A+W |
